Loading
A phase 2 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by RenJi Hospital, not yet recruiting.
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) is a phase 2, randomised interventional study registered as NCT06621095 by RenJi Hospital, with a registry enrolment figure of 104 participants, started 2024-10-30 and due to reach its primary completion in 2025-12-31. Interventions recorded: anlotinib + benmelstobart + nab-paclitaxel + gemcitabine; nab-paclitaxel + gemcitabine. Conditions listed: Pancreatic Cancer; First-line; Metastatic Pancreatic Cancer. Primary outcome: Objective response rate (ORR). Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed diagnosis of metastatic pancreatic cancer;". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/